eligibility_summary
Include: 18–65, consent, B‑cell NHL (e.g., DLBCL, MCL, FL3B, PMBCL, high‑grade, AIDS‑related), prior anti‑CD20 + anthracycline, measurable disease, ECOG ≤2/KPS ≥60, adequate renal/hepatic (CrCl >30, ALT ≤5×ULN, TBIL ≤2 mg/dL), LVEF ≥40%, ANC ≥1000, platelets ≥30k, CD19+ if previously targeted, negative pregnancy test/contraception, controlled HIV, HBV/HCV per protocol with HBV prophylaxis. Exclude: allergy to conditioning, uncontrolled infection, PE <3 mo, serious CV/cerebrovascular/hereditary disease, CNS involvement, allo‑HSCT <100 d, systemic steroids ≤3 d pre‑screen, influenza vaccine <2 wk pre‑lymphodepletion, pregnancy/lactation or plans within 1 yr.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase 1/2, single-arm, dose-escalation/expansion in relapsed/refractory CD19+ B‑cell lymphoma (including AIDS-related). Interventions and mechanisms: 1) ThisCART19A – allogeneic anti‑CD19 CAR‑T cell therapy. Donor T cells are genetically engineered with a CAR that binds CD19 on B cells, CAR signaling (via CD3ζ/co-stim domains) activates T‑cell cytotoxicity and cytokine release to eliminate malignant CD19+ B cells. 2) Lymphodepletion prior to infusion: fludarabine (purine analog antimetabolite inhibiting DNA synthesis), cyclophosphamide (alkylating agent), and etoposide/VP‑16 (topoisomerase II inhibitor). These reduce host lymphocytes to promote CAR‑T expansion/persistence. Targets: CD19 antigen on B cells, leading to depletion of malignant and normal B‑cell compartments, activation of T‑cell effector pathways post‑CAR engagement.